Results 351 to 360 of about 297,887 (387)
Some of the next articles are maybe not open access.
Related searches:
Related searches:
ACS Nano, 2022
In view of the lack of a specific drug-sustained release system that is responsive to chronic wounds of the type II diabetic foot, and the demands for frequent movement at the foot wound, pH/glucose dual-responsive metformin-released adhesion-enhanced ...
Yongping Liang +5 more
semanticscholar +1 more source
In view of the lack of a specific drug-sustained release system that is responsive to chronic wounds of the type II diabetic foot, and the demands for frequent movement at the foot wound, pH/glucose dual-responsive metformin-released adhesion-enhanced ...
Yongping Liang +5 more
semanticscholar +1 more source
Drugs, 2006 A fixed-dose pioglitazone/metformin tablet is approved in the US and the EU for the treatment of adult patients with type 2 diabetes mellitus who currently have inadequate glycaemic control with metformin monotherapy. In the US, the combination tablet is also approved for the treatment of adult patients with type 2 diabetes who currently have ...
Emma D. Deeks, Lesley J. Scott
openaire +2 more sources
Endocrinology and Metabolism Clinics of North America, 1997
Metformin, a dimethylbiguanide, was first synthesized in 1929 and was shown to be a potent hypoglycemic agent. It was rediscovered in 1957 and was widely used in Europe to treat obese type II patients. Metformin resurfaced in the 1980s and was shown to increase insulin sensitivity; this has led to its introduction to clinical practice in the United ...
P M, Bell, D R, Hadden
openaire +2 more sources
Metformin, a dimethylbiguanide, was first synthesized in 1929 and was shown to be a potent hypoglycemic agent. It was rediscovered in 1957 and was widely used in Europe to treat obese type II patients. Metformin resurfaced in the 1980s and was shown to increase insulin sensitivity; this has led to its introduction to clinical practice in the United ...
P M, Bell, D R, Hadden
openaire +2 more sources
Annals of Internal Medicine, 2002 Metformin is an insulin-sensitizing agent with potent antihyperglycemic properties. Its efficacy in reducing hyperglycemia in type 2 diabetes mellitus is similar to that of sulfonylureas, thiazolidinediones, and insulin. Metformin-based combination therapy is often superior to therapy with a single hypoglycemic agent.
Dmitri Kirpichnikov +2 more
openaire +2 more sources
Current Diabetes Reviews, 2020
Introduction: The Diabetes Prevention Program study results indicated that metformin therapy was not as beneficial as a lifestyle modification for delaying the development of type 2 diabetes in individuals at high risk of the disease. A key feature in the etiology of type 2 diabetes mellitus, which appears in the prediabetic phase, is a significant ...
Dick J. Bekedam, Rob N.M. Weijers
openaire +2 more sources
Introduction: The Diabetes Prevention Program study results indicated that metformin therapy was not as beneficial as a lifestyle modification for delaying the development of type 2 diabetes in individuals at high risk of the disease. A key feature in the etiology of type 2 diabetes mellitus, which appears in the prediabetic phase, is a significant ...
Dick J. Bekedam, Rob N.M. Weijers
openaire +2 more sources
Tijdschrift voor praktijkondersteuning, 2014
Na de ontdekking en internationale introductie in 1923 van insuline voor de behandeling van diabetes mellitus, is in 1959 metformine internationaal in de handel gebracht als een van de eerste orale bloedglucoseverlagende middelen.
openaire +2 more sources
Na de ontdekking en internationale introductie in 1923 van insuline voor de behandeling van diabetes mellitus, is in 1959 metformine internationaal in de handel gebracht als een van de eerste orale bloedglucoseverlagende middelen.
openaire +2 more sources
Drugs of Today, 2008
Metformin is a well-established ingredient of diabetes management, both as a monotherapy in early stages of type 2 diabetes and as adjunct therapy to virtually every other antihyperglycemic medicine available today. Despite low potency and a long list of contraindications, metformin has remained successful and even expanded experimental use due to its ...
openaire +2 more sources
Metformin is a well-established ingredient of diabetes management, both as a monotherapy in early stages of type 2 diabetes and as adjunct therapy to virtually every other antihyperglycemic medicine available today. Despite low potency and a long list of contraindications, metformin has remained successful and even expanded experimental use due to its ...
openaire +2 more sources